Your browser doesn't support javascript.
loading
ON/OFF non-motor evaluation: a new way to evaluate non-motor fluctuations in Parkinson's disease.
Faggianelli, Florent; Witjas, Tatiana; Azulay, J-P; Benatru, Isabelle; Hubsch, Cécile; Anheim, Mathieu; Moreau, Caroline; Hainque, Elodie; Drapier, Sophie; Jarraya, Béchir; Laurencin, Chloé; Guehl, Dominique; Hopes, Lucie; Brefel-Courbon, Christine; Tir, Melissa; Marques, Ana; Rouaud, Tiphaine; Maltete, David; Giordana, Caroline; Baumstarck, Karine; Rascol, Olivier; Corvol, Jean Christophe; Rolland, Anne-Sophie; Devos, David; Eusebio, Alexandre.
  • Faggianelli F; Neurology, CHU Timone, Marseille, France Florent.faggianelli@gmail.com.
  • Witjas T; Department of Neurology, University Hospital Timone, Marseille, France.
  • Azulay JP; CHU Timone, Marseille, France.
  • Benatru I; Centre Hospitalier Universitaire de Poitiers, Poitiers, France.
  • Hubsch C; Neurology, Fondation Ophtalmologique Adolphe de Rothschild, Paris, France.
  • Anheim M; Service de Neurologie, Hopital de Hautepierre, Strasbourg, France.
  • Moreau C; Neurology Expert Center for Parkinson's disease, University of Lille, Lille, France.
  • Hainque E; Département de Neurologie, APHP, Paris, France.
  • Drapier S; Neurologie, CHU Pontchaillou, Rennes, France.
  • Jarraya B; Neuroscience, Hospital Foch, Suresnes, Île-de-France, France.
  • Laurencin C; CNRS UMR 5229, Bron, France.
  • Guehl D; Centre Expert Parkinson, Bron, France.
  • Hopes L; Pôle de Neurosciences Cliniques, CHU de Bordeaux, Bordeaux, France.
  • Brefel-Courbon C; CNRS UMR 5293, Institut des Maladies Neurodegeneratives, Bordeaux, France.
  • Tir M; Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, Lorraine, France.
  • Marques A; Clinical Pharmacology and Neurosciences, University Hospital Centre Toulouse, Toulouse, Occitanie, France.
  • Rouaud T; Neurology, CHU Amiens-Picardie, Amiens, Hauts-de-France, France.
  • Maltete D; EA7280, Université Clermont Auvergne, Clermont-Ferrand, France.
  • Giordana C; Neurology, University Hospital Centre Clermont-Ferrand, Clermont-Ferrand, France.
  • Baumstarck K; Department of Neurology, Nantes University Hospital, Nantes, France.
  • Rascol O; Neurology, Rouen University Hospital, Rouen, France.
  • Corvol JC; Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, Lorraine, France.
  • Rolland AS; Aix Marseille Université, EA 3279 Self-Perceived Health Assessment Research Unit, Marseille, France.
  • Devos D; Pharmacology, Toulouse University, Toulouse, France.
  • Eusebio A; Department of Neurology, Hopital Pitie-Salpetriere, Paris, France.
J Neurol Neurosurg Psychiatry ; 95(7): 656-662, 2024 Jun 17.
Article en En | MEDLINE | ID: mdl-38272656
ABSTRACT

BACKGROUND:

NMF are currently poorly evaluated in therapeutic decisions. A quantification of their severity would facilitate their integration. The objective of this study was to validate an autoquestionnaire evaluating the severity of non-motor fluctuations (NMF) in Parkinson's disease (PD).

METHODS:

Patients with PD were included in presurgical situation for deep brain stimulation of subthalamic nuclei. They participated in the PREDISTIM cohort (a study evaluating the predictive factors for therapeutic response of subthalamic stimulation in PD) in 17 centres in France. Our questionnaire, resulting from previous phases of development, included 11 non-motor symptoms (NMS). Their severity ranged from 0 to 10 and was assessed in OFF and then ON-Dopa to study their fluctuations.

RESULTS:

310 patients were included, of whom 98.8% had NMS and 98.0% had NMF. Each NMS was significantly improved by L-Dopa (decrease in severity score ranging from 43.1% to 69.9%). Fatigue was the most frequent and most severe NMS. NMS were considered more bothersome than motor symptoms by 37.5% of patients in OFF-Dopa and 34.9% in ON-Dopa.

CONCLUSIONS:

This is the first questionnaire allowing a real-time quantification of the severity of NMS and their fluctuation with levodopa. It was able to confirm and measure the effect of L-dopa and show differences according to the patients and the NMS. It differs from other questionnaires by its measurement at a precise moment of the severity of the NMS, allowing its use during pretherapeutic assessments.Our questionnaire has been validated to measure the severity of NMF. It will be able to quantify the non-motor effect of anti-parkinsonian treatments and could facilitate the integration of NMF in therapeutic decisions.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Levodopa / Estimulación Encefálica Profunda / Antiparkinsonianos Tipo de estudio: Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Levodopa / Estimulación Encefálica Profunda / Antiparkinsonianos Tipo de estudio: Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2024 Tipo del documento: Article